All In Biotech

NDA 020816 · Sandoz

Azopt

Brinzolamide · Ophthalmic · Carbonic Anhydrase Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Jun 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Apr 1, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

69

20 Phase 3, 1 recruiting

FAERS reports

8,693

5,215 serious, 645 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 24, 2023.

AZOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. AZOPT is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. ( 1 )

Mechanism: Carbonic anhydrase is an enzyme found in many tissues of the body, including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II, found primarily in red blood cells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AZOPT · BRINZOLAMIDE 1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Brinzolamide" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure1,429
  • dyspnoea590
  • drug ineffective512
  • dizziness503
  • eye pain491
  • fatigue476
  • diarrhoea469
  • fall454
  • headache446
  • vision blurred427
  • asthenia416
  • malaise396

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200426
200532
200658
200745
200884
2009138
2010183
2011190
2012242
2013290
2014368
2015436
2016550
2017545
2018673
2019583
20201,947
2021429
2022490
2023381
2024421
2025357
2026225

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azopt (Brinzolamide)

2024 spending

$14.5M

Beneficiaries

8,968

30,493 claims

Per beneficiary

$1,615

$35.40 per unit

View as table
YearSpending
2020$0
2021$0
2022$16,136,852
2023$21,806,627
2024$14,483,551

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 101 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.